Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29639366 | 1.00 | LMNA (0.53) | LMNAHTTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL30542253 | 0.84 | SMN1; SMN2 (0.49) | LMNAHTTALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL145336 | 0.84 | SMN1; SMN2 (0.49) | LMNAHTTALDH1A1SMN1; SMN2CYP2C19 | |
| SCHEMBL5814377 | 0.82 | HTT (0.54) | LMNAHTTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5525050 | 0.81 | SIGMAR1 (0.50) | LMNAALDH1A1KDM4EMAPTL3MBTL1 | |
| SCHEMBL28880172 | 0.81 | L3MBTL1 (0.56) | LMNAALDH1A1SMN1; SMN2NPC1CYP2C19 | |
| SCHEMBL6833378 | 0.81 | POLB (0.51) | ALDH1A1NPC1MAPTKMT2A | |
| SCHEMBL29586280 | 0.81 | GAA (0.53) | LMNAHTTALDH1A1KDM4EMAPT | |
| SCHEMBL28563284 | 0.81 | LMNA (0.58) | LMNAHTTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL24356073 | 0.80 | HTT (0.56) | LMNAHTTALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114432901-B | Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-114432901-A | Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-112582673-A | Lithium ion battery electrolyte and lithium ion battery | 比亚迪股份有限公司 | 2021-03-30 | — | — | CN | claimed |
| US-12630515-B2 | Small molecule prostagladin transport inhibitors | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4054608-B1 | SMALL MOLECULE PROSTAGLADIN TRANSPORT INHIBITORS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250092020-A1 | IDO/TDO Inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-20230129765-A1 | METHOD FOR PRODUCING POLYTHIOETHER COMPOUND | DAICEL CORPORATION (JP) | 2023-04-27 | — | — | US | disclosed |
| CN-114432901-B | Composite membrane with acid resistance and alkali resistance as well as preparation method and application thereof | 中国石油化工股份有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-04-17 | — | — | US | disclosed |
| EP-2700636-A1 | PROCESS FOR PREPARING EPISULFIDE COMPOUNDS | Asahi Kasei Chemicals Corporation (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | BAYER HEALTHCARE AG LAW AND PATENTS,PATENTS AND LICENSING (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | BAYER HEALTHCARE AG (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | OPTIMER PHOTONICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| EP-1467981-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | Kylix Pharmaceuticals B.V. (NL) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003062215-A1 | 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 | KYLIX PHARMACEUTICALS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | LMNA 4867/4885HTT 71/4885ALDH1A1 3331/4885 |
| US-20100048641-A1 | Use of Adenosine A1 and/or Dual A1/2ab Agonists for Production of Medicaments for Treating Diseases | ADORA1, ADORA2B, ADORA2A | LMNA 786/4885HTT 3910/4885ALDH1A1 312/4885 |
| US-20080269300-A1 | Substituted Phenylaminothiazoles and Use Thereof | PAH, TNNT2, VHL | LMNA 597/4885HTT 488/4885ALDH1A1 739/4885 |
| US-20120059163-A1 | Non-linear opticaly active molecules, their synthesis, and use | INCENP, CYBA, ADCY5 | LMNA 493/4885HTT 2237/4885ALDH1A1 371/4885 |
| US-20250092020-A1 | IDO/TDO Inhibitor | IDO1, IDO2, TDO2 | LMNA 4867/4885HTT 71/4885ALDH1A1 3331/4885 |
| US-12630515-B2 | Small molecule prostagladin transport inhibitors | PTGER1, PTGS1, PTGIR | LMNA 2813/4885HTT 3283/4885ALDH1A1 1715/4885 |
| US-20080004415-A1 | Non-linear optically active molecules, their synthesis, and use | INCENP, CYBA, PAICS | LMNA 289/4885HTT 1652/4885ALDH1A1 378/4885 |
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | TST, EPHX2, STS | LMNA 3658/4885HTT 2353/4885ALDH1A1 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.